RxDoctor Payments DataLook up a doctor →

Carol Levy, MD

Endocrinology, Diabetes & Metabolism · New York, NYNPI 1710074893

Payments from drug & device makers

$2,169,980in general payments, 2019–2025

Across 370 payments — averaging $5864.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Dexcom, Inc.$894K
  • Insulet Corporation$467K
  • Tandem Diabetes Care, Inc.$364K
  • Sequel Med Tech, LLC$237K
  • Mannkind Corporation$146K
  • Abbott$43K
  • plus $19K from 7 others

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,169,980 in reported general payments places this provider in the 95th percentile of 804 endocrinology, diabetes & metabolism providers in New York.

See all endocrinology, diabetes & metabolism providers in New York

Medicare billing

Part B allowed, 2024
$23,297
Medicare patients
47
Services billed
221

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other endocrinology, diabetes & metabolism in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →